Constructive Bio, a pioneer in synthetic genomics, has successfully raised £43.4m.
- Founded in 2021, the firm focuses on developing programmable molecules.
- The funding round was led by Ahren, OMX Ventures and Paladin Capital Group.
- Constructive Bio aims to innovate biomanufacturing with their proprietary technology.
- This injection raises their total funding to $75m, with plans to advance therapeutic treatments.
Constructive Bio, established in 2021, has secured £43.4m in the first close of its Series A funding round. The Cambridge-based startup specialises in developing programmable molecules through their genomics synthesis process. The company’s innovative approach aims to engineer molecules with novel properties to support advancements in pharmaceutical and therapeutic treatments.
The recent funding round was led by Ahren, OMX Ventures, and Paladin Capital Group. With this latest investment, Constructive Bio’s total raised capital has reached $75m. This financial backing highlights the growing confidence in Constructive Bio’s potential to revolutionise biomanufacturing through its novel technologies.
Professor Jason Chin, the founder of Constructive Bio, emphasised that they have a unique capability in transforming living cells into sustainable biofactories. ‘We can programme the sequence, composition, and chemistry of proteins and new biopolymers,’ he stated. This technology is underpinned by their three foundational platforms: deeply recoded synthetic genomes, engineered cellular machinery, and new chemistry.
Additional contributions to this funding round came from Fine Structure Ventures, +ND Capital, and Abcam founder Jonathan Milner. These investments underscore the strong belief in Constructive Bio’s capacity to deliver breakthrough medicines, enzymes, and biomaterials in the future. Paul Conley, managing director of Paladin Capital, remarked on the impressive evolution of Constructive Bio’s bioengineering platform technologies, acknowledging the potential impact they have on the future of medicine.
Constructive Bio’s significant funding achievement marks a pivotal step in advancing their innovative genomics technologies for therapeutic development.
